Curium Acquires Lantheus in $8B Radiopharma Deal

In a significant consolidation within the nuclear medicine sector, Curium has agreed to acquire Lantheus Holdings, Inc. in a transaction valued at up to $8 billion. This strategic combination aims to forge a global leader in radiopharmaceuticals, spanning both diagnostic and therapeutic applications. The deal, structured with an upfront cash payment and contingent value rights (CVRs) tied to future product performance, underscores the growing importance and commercial potential of targeted radionuclide therapies and advanced imaging agents.

Under the terms of the definitive agreement, Curium US Holdings LLC will purchase all outstanding Lantheus shares for $102.50 per share in cash. Additionally, Lantheus shareholders stand to receive up to $12.00 per share in CVRs, contingent upon the successful commercialization of key Lantheus products through 2030. This structure offers immediate value certainty while allowing shareholders to participate in the future success of the combined entity's product portfolio. The total per-share consideration could reach $114.50.

The acquisition represents a substantial premium for Lantheus shareholders, reflecting the strategic value of its established U.S. commercial infrastructure and its leading diagnostic products. The transaction value signifies a 38% premium over Lantheus’ 60-day unaffected volume-weighted average price prior to initial deal speculation. This move is expected to create a formidable player with the capacity to serve patients in over 70 countries, integrating Curium's global manufacturing and therapeutic pipeline with Lantheus' strong diagnostic franchise.

Renaud Dehareng, CEO of Curium Group, highlighted the synergistic benefits, stating, “Lantheus is the ideal partner to accelerate what we have been building at Curium.” He emphasized Curium's strategy of developing a theranostics platform and how Lantheus' complementary business, particularly its F18-isotope based prostate diagnostics and entry into U.S. diagnostic solutions for Neurology and Echocardiography, significantly enhances this vision. The combined company anticipates offering a comprehensive suite of theranostic options, from SPECT and PET diagnostics to targeted radioligand therapies.

Mary Anne Heino, Executive Chair and CEO of Lantheus, viewed the transaction as a validation of the company's seven-decade innovation in radiopharmaceuticals. She noted the shared passion for nuclear medicine and the potential to broaden and accelerate patient access to life-changing diagnostics and therapeutics. Lantheus brings a proven track record with products like PYLARIFY for prostate cancer imaging, DEFINITY for cardiac ultrasound, and Neuraceq for amyloid PET imaging.

This transaction is strongly supported by CapVest Partners LLP, Curium's controlling shareholder. Kate Briant, Senior Partner at CapVest and Chair of Curium’s Board, reiterated CapVest's commitment to Curium's growth and its conviction in the nuclear medicine sector. CapVest previously oversaw a recapitalization of Curium that valued the group at approximately $7 billion last year. The integration is poised to leverage the full nuclear medicine value chain, from isotope production to advanced therapies, addressing a critical need for integrated solutions in oncology and other therapeutic areas.

The nuclear medicine market is experiencing robust growth, driven by advancements in diagnostic imaging and targeted therapies for diseases like cancer. The combined entity's expanded global reach and comprehensive product portfolio position it to capitalize on these trends, offering a more complete solution for healthcare providers and patients worldwide. This merger is anticipated to drive significant innovation and market penetration in the rapidly evolving field of radiopharmaceuticals.